HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Therapeutic delivery of hydrogen sulfide for salvage of ischemic skeletal muscle after the onset of critical ischemia.

AbstractBACKGROUND:
Recent evidence suggests that hydrogen sulfide is capable of mitigating the degree of cellular damage associated with ischemia-reperfusion injury (IRI).
METHODS:
This study evaluated the potential utility of hydrogen sulfide in preventing IRI in skeletal muscle by using in vitro (cultured myotubes subjected to sequential hypoxia and normoxia) and in vivo (mouse hind limb ischemia, followed by reperfusion) models to determine whether intravenous hydrogen sulfide delivered after the ischemic event had occurred (pharmacologic postconditioning) conferred protection against IRI. Injury score and apoptotic index were determined by analysis of specimens stained with hematoxylin and eosin and terminal deoxynucleotide transferase-mediated deoxy-uridine triphosphate nick-end labeling, respectively.
RESULTS:
In vitro, hydrogen sulfide reduced the apoptotic index after 1, 3, or 5 hours of hypoxia by as much as 75% (P = .002), 80% (P = .006), and 83% (P < .001), respectively. In vivo, hydrogen sulfide delivered after the onset of hind limb ischemia and before reperfusion resulted in protection against IRI-induced cellular changes, which was validated by significant decreases in the injury score and apoptotic index. The timing of hydrogen sulfide delivery was crucial: when delivered 20 minutes before reperfusion, hydrogen sulfide conferred significant cytoprotection (P < .001), but treatment 1 minute before reperfusion did not provide protection (P = NS).
CONCLUSIONS:
These findings confirm that hydrogen sulfide limits IRI-induced cellular damage in myotubes and skeletal muscle, even when delivered after the onset of ischemia in this murine model. These data suggest that when given in the appropriate dose and within the proper time frame, hydrogen sulfide may have significant therapeutic applications in multiple clinical scenarios.
AuthorsPeter W Henderson, Natalia Jimenez, John Ruffino, Allie M Sohn, Andrew L Weinstein, David D Krijgh, Alyssa J Reiffel, Jason A Spector
JournalJournal of vascular surgery (J Vasc Surg) Vol. 53 Issue 3 Pg. 785-91 (Mar 2011) ISSN: 1097-6809 [Electronic] United States
PMID21215566 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011. Published by Mosby, Inc.
Chemical References
  • Sulfides
  • sodium bisulfide
Topics
  • Animals
  • Apoptosis (drug effects)
  • Cell Hypoxia
  • Cell Line
  • Critical Illness
  • Cytoprotection
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Hindlimb
  • Injections, Intravenous
  • Ischemia (drug therapy, pathology)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Muscle, Skeletal (blood supply, drug effects, pathology)
  • Myoblasts, Skeletal (drug effects, pathology)
  • Reperfusion Injury (pathology, prevention & control)
  • Severity of Illness Index
  • Sulfides (administration & dosage)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: